Cargando…
Neuroendocrine Differentiation of Prostate Cancer Metastases Evidenced “in Vivo” by (68)Ga-DOTANOC PET/CT: Two Cases
Prostate cancer is the second most commonly diagnosed neoplasm in men. This neoplasm has usually excellent prognosis, mostly consequent to the early diagnosis and the effective hormonal therapy. However, significant percentages of patients treated with total androgen blockade therapy, escape to trea...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649877/ https://www.ncbi.nlm.nih.gov/pubmed/29147381 http://dx.doi.org/10.14740/wjon739w |
_version_ | 1783272624094183424 |
---|---|
author | Savelli, Giordano Muni, Alfredo Barbieri, Roberto Valmadre, Giuseppe Biasiotto, Giorgio Minari, Chiara Ghimenton, Claudio Pagani, Renato Pecini, Elisa Falcone, Matteo |
author_facet | Savelli, Giordano Muni, Alfredo Barbieri, Roberto Valmadre, Giuseppe Biasiotto, Giorgio Minari, Chiara Ghimenton, Claudio Pagani, Renato Pecini, Elisa Falcone, Matteo |
author_sort | Savelli, Giordano |
collection | PubMed |
description | Prostate cancer is the second most commonly diagnosed neoplasm in men. This neoplasm has usually excellent prognosis, mostly consequent to the early diagnosis and the effective hormonal therapy. However, significant percentages of patients treated with total androgen blockade therapy, escape to treatment and evolve toward a more aggressive type of cancer. This clinical entity, named castration-resistant prostate cancer, has few and less effective therapeutic opportunities. Therefore, any additional information concerning possible biological targets to therapy is welcome. Here we describe two cases in which (68)Ga-DOTANOC PET/CT evidenced the somatostatin receptor overexpression by prostate metastases. The presence of these receptors may support with a more strong evidence the possibility to administer somatostatin analogs as an adjuvant therapy. |
format | Online Article Text |
id | pubmed-5649877 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Elmer Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-56498772017-11-16 Neuroendocrine Differentiation of Prostate Cancer Metastases Evidenced “in Vivo” by (68)Ga-DOTANOC PET/CT: Two Cases Savelli, Giordano Muni, Alfredo Barbieri, Roberto Valmadre, Giuseppe Biasiotto, Giorgio Minari, Chiara Ghimenton, Claudio Pagani, Renato Pecini, Elisa Falcone, Matteo World J Oncol Case Report Prostate cancer is the second most commonly diagnosed neoplasm in men. This neoplasm has usually excellent prognosis, mostly consequent to the early diagnosis and the effective hormonal therapy. However, significant percentages of patients treated with total androgen blockade therapy, escape to treatment and evolve toward a more aggressive type of cancer. This clinical entity, named castration-resistant prostate cancer, has few and less effective therapeutic opportunities. Therefore, any additional information concerning possible biological targets to therapy is welcome. Here we describe two cases in which (68)Ga-DOTANOC PET/CT evidenced the somatostatin receptor overexpression by prostate metastases. The presence of these receptors may support with a more strong evidence the possibility to administer somatostatin analogs as an adjuvant therapy. Elmer Press 2014-04 2014-05-06 /pmc/articles/PMC5649877/ /pubmed/29147381 http://dx.doi.org/10.14740/wjon739w Text en Copyright 2014, Savelli et al. http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Savelli, Giordano Muni, Alfredo Barbieri, Roberto Valmadre, Giuseppe Biasiotto, Giorgio Minari, Chiara Ghimenton, Claudio Pagani, Renato Pecini, Elisa Falcone, Matteo Neuroendocrine Differentiation of Prostate Cancer Metastases Evidenced “in Vivo” by (68)Ga-DOTANOC PET/CT: Two Cases |
title | Neuroendocrine Differentiation of Prostate Cancer Metastases Evidenced “in Vivo” by (68)Ga-DOTANOC PET/CT: Two Cases |
title_full | Neuroendocrine Differentiation of Prostate Cancer Metastases Evidenced “in Vivo” by (68)Ga-DOTANOC PET/CT: Two Cases |
title_fullStr | Neuroendocrine Differentiation of Prostate Cancer Metastases Evidenced “in Vivo” by (68)Ga-DOTANOC PET/CT: Two Cases |
title_full_unstemmed | Neuroendocrine Differentiation of Prostate Cancer Metastases Evidenced “in Vivo” by (68)Ga-DOTANOC PET/CT: Two Cases |
title_short | Neuroendocrine Differentiation of Prostate Cancer Metastases Evidenced “in Vivo” by (68)Ga-DOTANOC PET/CT: Two Cases |
title_sort | neuroendocrine differentiation of prostate cancer metastases evidenced “in vivo” by (68)ga-dotanoc pet/ct: two cases |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649877/ https://www.ncbi.nlm.nih.gov/pubmed/29147381 http://dx.doi.org/10.14740/wjon739w |
work_keys_str_mv | AT savelligiordano neuroendocrinedifferentiationofprostatecancermetastasesevidencedinvivoby68gadotanocpetcttwocases AT munialfredo neuroendocrinedifferentiationofprostatecancermetastasesevidencedinvivoby68gadotanocpetcttwocases AT barbieriroberto neuroendocrinedifferentiationofprostatecancermetastasesevidencedinvivoby68gadotanocpetcttwocases AT valmadregiuseppe neuroendocrinedifferentiationofprostatecancermetastasesevidencedinvivoby68gadotanocpetcttwocases AT biasiottogiorgio neuroendocrinedifferentiationofprostatecancermetastasesevidencedinvivoby68gadotanocpetcttwocases AT minarichiara neuroendocrinedifferentiationofprostatecancermetastasesevidencedinvivoby68gadotanocpetcttwocases AT ghimentonclaudio neuroendocrinedifferentiationofprostatecancermetastasesevidencedinvivoby68gadotanocpetcttwocases AT paganirenato neuroendocrinedifferentiationofprostatecancermetastasesevidencedinvivoby68gadotanocpetcttwocases AT pecinielisa neuroendocrinedifferentiationofprostatecancermetastasesevidencedinvivoby68gadotanocpetcttwocases AT falconematteo neuroendocrinedifferentiationofprostatecancermetastasesevidencedinvivoby68gadotanocpetcttwocases |